Q&A with John Carey: Peeling back the label on cholesterol drugs
John Carey, a 20-year veteran at BusinessWeek, wrote a story that set the pharmaceutical world on its ear in January 2008. Titled "Do Cholesterol Drugs Do Any Good?," the article systematically broke...
View ArticleQ&A with Dr. Daniel Carlat: Finding an independent voice in a...
Even in his infamy, Dr. Daniel Carlat, founder of The Carlat Psychiatry Report, is popular with drug companies. Carlat was invited recently by Schering-Plough to help promote a new drug.
View ArticleThe Mittleman Files, Part 2: Just another day on the ghostwriting assembly line
Putting together a scientific research paper should be a different process than building a Ford Taurus or making a Big Mac.For the drug companies and their ghostwriting partners, it isn’t.
View ArticleThe Markingson Files: Conflicts of interest in clinical trials should be...
It can be uncomfortable asking people about their finances. In journalism, though, there is an obligation not only to ask, but to ask for proof — especially with clinical trials.
View ArticleFull Disclosure: Universities Should Make Ghostwriting Disappear
Shannon Brownlee offers a not-so-modest proposal for universities to stamp out pharma ghostwriting benefiting researchers.
View ArticleIt's Complicated: Taking Conflict of Interest Beyond Pharma Payments to...
I wrote a piece recently for Health News Review about conflicts of interest. The original post is below, followed by more great examples of writers describing unexpected conflicts in detail.
View ArticleQ&A with Leigh Turner: Tracking Medical Tourism Consequences
Bioethicist Leigh Turner, recently under fire from a stem cell company he criticized for ethical problems, talks about his research on medical tourism.
View ArticleLittle Known Livestock Drug at Heart of US/Russia Trade Dispute
A drug many people are eating without knowing it is starting a trade dispute between Russia and the US. This week, Russia announced it will turn away US beef and pork imports unless the US can certify...
View ArticleVeterinary Drug Residues in Food? Probably
"Animal Pharma," the animal-drug divisions within drug companies, tends to operate under the public's radar.
View ArticleSanitation and Disease Concerns Linked to U.S. Pork
You know things are bad in the pork industry when the whistleblowers aren't animal rights activists but the government itself. In May, the US Department of Agriculture's (USDA) Office of the Inspector...
View ArticleWill Risperdal Settlement Change Anything?
Many say the only justice that will get Big Pharma's attention is frog marching the CEOs off to prison and/or cutting them off from their lucrative public trough of Medicare, Medicaid and military...
View ArticleThe American Heart Association--Protecting Industry Not Patients by Barbara...
The American Heart Association (AHA) and the American College of Cardiology (ACC) recently released new cardiovascular disease prevention guidelines. They are an egregious example of much that is wrong...
View ArticleIf off-label marketing is 'speech,' why even have the FDA?
It has always been legal for U.S. doctors to prescribe drugs for off-label uses but marketing of off-label uses has been illegal.
View ArticleQ&A with John Carey: Peeling back the label on cholesterol drugs
John Carey, a 20-year veteran at BusinessWeek, wrote a story that set the pharmaceutical world on its ear in January 2008. Titled "Do Cholesterol Drugs Do Any Good?," the article systematically broke...
View ArticleQ&A with Dr. Daniel Carlat: Finding an independent voice in a...
Even in his infamy, Dr. Daniel Carlat, founder of The Carlat Psychiatry Report, is popular with drug companies. Carlat was invited recently by Schering-Plough to help promote a new drug.
View ArticleThe Mittleman Files, Part 2: Just another day on the ghostwriting assembly line
Putting together a scientific research paper should be a different process than building a Ford Taurus or making a Big Mac.For the drug companies and their ghostwriting partners, it isn’t.
View ArticleThe Markingson Files: Conflicts of interest in clinical trials should be...
It can be uncomfortable asking people about their finances. In journalism, though, there is an obligation not only to ask, but to ask for proof — especially with clinical trials.
View ArticleFull Disclosure: Universities Should Make Ghostwriting Disappear
Shannon Brownlee offers a not-so-modest proposal for universities to stamp out pharma ghostwriting benefiting researchers.
View Article